ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
1,2,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
1,3,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1,4,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1,5,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
2,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
3,1,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
4,1,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
4,2,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
4,3,Pharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
4,4,Rash pustular,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
5,1,Abortion missed,Abortions not specified as induced or spontaneous,Abortions and stillbirth,Preg,N
6,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
7,1,Gynaecomastia,Breast disorders NEC,Breast disorders,Repro,N
8,1,Pulmonary fibrosis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
9,1,Coeliac disease,Malabsorption syndromes,Malabsorption conditions,Gastr,N
9,2,Dermatitis herpetiformis,Bullous conditions,Epidermal and dermal conditions,Skin,N
9,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
9,4,Metabolic acidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
9,5,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
10,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
10,2,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
11,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
11,2,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
12,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
12,2,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
13,1,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
14,1,Ataxia,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
15,1,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
16,1,Anal cancer,Anal canal neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
16,2,Anal skin tags,Anal and rectal disorders NEC,Anal and rectal conditions NEC,Gastr,N
16,3,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
16,4,Spleen disorder,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
17,1,Cholestasis,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
18,1,Toxic epidermal necrolysis,Bullous conditions,Epidermal and dermal conditions,Skin,N
19,1,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
20,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
20,2,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
20,3,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
21,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
22,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
22,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
22,3,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
23,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
24,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
24,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
25,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
25,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
26,1,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
26,2,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,Y
27,1,Cardiomyopathy,Cardiomyopathies,Myocardial disorders,Card,N
28,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
28,2,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
28,3,Jaundice cholestatic,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
29,1,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
30,1,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
30,2,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
30,3,Incontinence,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
31,1,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
31,2,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
31,3,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
32,1,Full blood count abnormal,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
32,2,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
33,1,Full blood count abnormal,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
33,2,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
34,1,Hypogammaglobulinaemia,Immunodeficiency disorders NEC,Immunodeficiency syndromes,Immun,N
35,1,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
35,2,Enzyme level increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
35,3,Liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
36,1,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
36,2,Stress cardiomyopathy,Cardiomyopathies,Myocardial disorders,Card,N
37,1,Allodynia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
37,2,Pain of skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
37,3,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
38,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
38,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
38,3,Pulmonary fibrosis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
39,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
39,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
39,3,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
39,4,Septic shock,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
39,5,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
40,1,Acute hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
41,1,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
42,1,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
43,1,Choluria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
43,2,Drug-induced liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
43,3,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
43,4,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
43,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
43,6,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
44,1,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
44,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
44,3,Toxic epidermal necrolysis,Bullous conditions,Epidermal and dermal conditions,Skin,N
45,1,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
46,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
46,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
46,3,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
47,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
48,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
49,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
50,1,Haematotoxicity,Haematological disorders,Haematological disorders NEC,Blood,N
50,2,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
51,1,Haematotoxicity,Haematological disorders,Haematological disorders NEC,Blood,N
52,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
52,2,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
52,3,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
52,4,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
52,5,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
52,6,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
53,1,Microangiopathic haemolytic anaemia,Anaemias haemolytic mechanical factor,Haemolyses and related conditions,Blood,N
53,2,Thrombotic thrombocytopenic purpura,Thrombocytopenias,Platelet disorders,Blood,N
